{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:37:50Z","timestamp":1786991870104,"version":"build-2736575974"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jconrel.2022.05.061","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T05:34:10Z","timestamp":1662615250000},"page":"1045-1051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions"],"prefix":"10.1016","volume":"349","author":[{"given":"Viral S.","family":"Kansara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley E.","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leroy W.","family":"Muya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Ciulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.jconrel.2022.05.061_bb0005","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.061_bb0010","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","article-title":"Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study","volume":"123","author":"Clark","year":"2016","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.jconrel.2022.05.061_bb0015","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ophtha.2014.08.031","article-title":"Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study","volume":"122","author":"Campochiaro","year":"2015","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.jconrel.2022.05.061_bb0020","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ajo.2012.09.026","article-title":"Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study","volume":"155","author":"Brown","year":"2013","journal-title":"Am J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.061_bb0025","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ophtha.2013.08.012","article-title":"Intravitreal Aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.jconrel.2022.05.061_bb0030","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.jconrel.2022.05.061_bb0035","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.038","article-title":"Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.jconrel.2022.05.061_bb0040","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.061_bb0045","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.jconrel.2022.05.061_bb0050","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","article-title":"Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.jconrel.2022.05.061_bb0055","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/bjophthalmol-2020-317337","article-title":"Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes","volume":"105","author":"Ciulla","year":"2021","journal-title":"Br. J. Ophthalmol."},{"issue":"12","key":"10.1016\/j.jconrel.2022.05.061_bb0060","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.oret.2018.06.004","article-title":"Real-world outcomes of anti-vascular endothelial growth factor therapy in diabetic macular edema in the United States","volume":"2","author":"Ciulla","year":"2018","journal-title":"Ophthalmol. Retin."},{"issue":"12","key":"10.1016\/j.jconrel.2022.05.061_bb0065","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.ophtha.2013.05.018","article-title":"A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration","volume":"120","author":"Rasmussen","year":"2013","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.061_bb0070","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ophtha.2015.09.039","article-title":"First-year visual acuity outcomes of providing Aflibercept according to the VIEW study protocol for age-related macular degeneration","volume":"123","author":"Talks","year":"2016","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.061_bb0075","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/aos.12610","article-title":"A prospective, observational, open-label, multicentre study to investigate the daily treatment practice of ranibizumab in patients with neovascular age-related macular degeneration","volume":"93","author":"van Asten","year":"2015","journal-title":"Acta Ophthalmol."},{"issue":"10","key":"10.1016\/j.jconrel.2022.05.061_bb0080","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.ophtha.2014.04.026","article-title":"The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes","volume":"121","author":"Zarranz-Ventura","year":"2014","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.061_bb0085","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","article-title":"Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS registry","volume":"125","author":"Rao","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2022.05.061_bb0090","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2147\/OPTH.S128509","article-title":"Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO study report 1)","volume":"11","author":"Blinder","year":"2017","journal-title":"Clin. Ophthalmol."},{"issue":"3","key":"10.1016\/j.jconrel.2022.05.061_bb0095","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3928\/23258160-20160229-09","article-title":"Diabetic macular edema diagnosis and treatment in the real world: an analysis of Medicare claims data (2008 to 2010)","volume":"47","author":"Dugel","year":"2016","journal-title":"Ophthalmic Surg. Lasers Imaging Retina"},{"key":"10.1016\/j.jconrel.2022.05.061_bb0100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ajo.2018.04.010","article-title":"Vision outcomes following anti-vascular endothelial growth factor treatment of diabetic macular edema in clinical practice","volume":"191","author":"Holekamp","year":"2018","journal-title":"Am J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.061_bb0105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","article-title":"Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in Neovascular age-related macular degeneration patients: a real-world analysis of 49485 eyes","volume":"4","author":"Ciulla","year":"2020","journal-title":"Ophthalmol. Retin."},{"key":"10.1016\/j.jconrel.2022.05.061_bb0110","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2147\/OPTH.S60893","article-title":"Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema","volume":"8","author":"Kiss","year":"2014","journal-title":"Clin. Ophthalmol."},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.061_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149450","article-title":"Trends in the Care of Diabetic Macular Edema: analysis of a National Cohort","volume":"11","author":"VanderBeek","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jconrel.2022.05.061_bb0120","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ophtha.2019.10.019","article-title":"Treatment patterns for diabetic macular edema: an intelligent research in sight (IRIS\u00ae) registry analysis","volume":"127","author":"Cantrell","year":"2020","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.061_bb0125","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/bjophthalmol-2020-315836","article-title":"Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser","volume":"105","author":"Gale","year":"2021","journal-title":"Br. J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.jconrel.2022.05.061_bb0130","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/IAE.0000000000000827","article-title":"Intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: 5-year results of the Pan-American collaborative retina study group","volume":"36","author":"Arevalo","year":"2016","journal-title":"Retina"},{"issue":"9","key":"10.1016\/j.jconrel.2022.05.061_bb0135","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1097\/IAE.0000000000000548","article-title":"CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE: the TWIN study","volume":"35","author":"Souied","year":"2015","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.061_bb0140","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.061_bb0145","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ajo.2012.06.031","article-title":"Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment","volume":"155","author":"Kr\u00fcger Falk","year":"2013","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2022.05.061_bb0150","first-page":"1849","article-title":"Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study","volume":"7","author":"Rakic","year":"2013","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.jconrel.2022.05.061_bb0160","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.ophtha.2011.07.027","article-title":"Randomized comparision of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior and panuveitis: the mulcticenter uveitis steroid treatment trial","volume":"118","author":"Kempen","year":"2011","journal-title":"Opthalmology"},{"key":"10.1016\/j.jconrel.2022.05.061_bb0165","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/j.ophtha.2015.06.041","article-title":"The risk of intraocular pressure elevation in pediatric noninffectious uveitits","volume":"122","author":"Kothari","year":"2015","journal-title":"Ophthalmology."},{"key":"10.1016\/j.jconrel.2022.05.061_bb0170","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.ophtha.2014.05.021","article-title":"Periocular corticosteroid injections in uveitis: effects and complications","volume":"121","author":"Sen","year":"2014","journal-title":"Ophthalmology."},{"key":"10.1016\/j.jconrel.2022.05.061_bb0175","doi-asserted-by":"crossref","unstructured":"Cho et al., A three-year follow -up of intravitreal triamcinolone acetonide injection and macular laser photocoagulation for diffuse diabetic macular edema. Korean J. Ophthalmol., vol 26, 362\u2013368, doi:https:\/\/doi.org\/10.3341\/kjo.2012.26.5.362.","DOI":"10.3341\/kjo.2012.26.5.362"},{"key":"10.1016\/j.jconrel.2022.05.061_bb0180","doi-asserted-by":"crossref","DOI":"10.1111\/aos.14042","article-title":"Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach","author":"Habot-Wilner","year":"2019","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.jconrel.2022.05.061_bb0185","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.12-9872","article-title":"Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye","author":"Patel","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2022.05.061_bb0190","first-page":"1","article-title":"Biomechanics of suprachoroidal drug delivery: From benchtop to clinical investigation in ocular therapies","author":"Hancock","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"issue":"7","key":"10.1016\/j.jconrel.2022.05.061_bb0195","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","article-title":"Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial","volume":"127","author":"Yeh","year":"2020","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.jconrel.2022.05.061_bb0200","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1167\/tvst.9.11.27","article-title":"Clinical characterization of Suprachoroidal injection procedure utilizing a microinjector across three retinal disorders","volume":"9","author":"Wan","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"issue":"7","key":"10.1016\/j.jconrel.2022.05.061_bb0205","first-page":"3615","article-title":"Ocular distribution and efficacy after suprachoroidal injection of AU-011 for treatment of ocular melanoma","volume":"61","author":"Savinainen","year":"2020","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2022.05.061_bb0210","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.13-11747","article-title":"Treatment of acute posterior uveitis in a porcine model by injection of triamcinolone acetonide into the suprachoroidal space using microneedles","author":"Gilger","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"Supplement","key":"10.1016\/j.jconrel.2022.05.061_bb0215","first-page":"4161","article-title":"Targeting, compartmentalization and durability of suprachoroidally injected small molecule suspensions in multiple preclinical models","volume":"63","author":"Kansara","year":"2002","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.061_bb0220","first-page":"233","article-title":"Hydrostatic pressure of the suprachoroidal space","volume":"30","author":"Emi","year":"1989","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.061_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics13020288","article-title":"Suprachoroidal delivery of small molecules, nanoparticles, gene and cell therapies for ocular diseases","volume":"13","author":"Wan","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.061_bb0230","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1167\/iovs.16-20377","article-title":"Thickness and closure kinetics of the Suprachoroidal space following microneedle injection of liquid formulations","volume":"58","author":"Chiang","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2022.05.061_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2016.10.011","article-title":"Distribution of particles, small molecules and polymeric formulation excipients in the suprachoroidal space after microneedle injection","volume":"153","author":"Chiang","year":"2016","journal-title":"Exp Eye Res."},{"key":"10.1016\/j.jconrel.2022.05.061_bb0240","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.exer.2016.03.008","article-title":"Circumferetnial flow of particles in the suprachoroidal space is impeded by the posterior ciliary arteries","volume":"145","author":"Chiang","year":"2016","journal-title":"Exp. Eye Res."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.061_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2040-2384-2-14","article-title":"Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability","volume":"2","author":"Sarin","year":"2010","journal-title":"J. Angiogenes. Res."},{"key":"10.1016\/j.jconrel.2022.05.061_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119935","article-title":"Sustained delivery of acraflavine from the suprachoroidal space provides long term supression of choroidal neovascularization","volume":"243","author":"Hackett","year":"2020","journal-title":"Biomaterials"},{"issue":"8","key":"10.1016\/j.jconrel.2022.05.061_bb0265","first-page":"2194","article-title":"Long-acting potential of suprachoroidally delivered BCX4161, a selective plasma kallikrein inhibitor, for diabetic macular edema","volume":"62","author":"Muya","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2022.05.061_bb0270","doi-asserted-by":"crossref","DOI":"10.1167\/tvst.10.7.19","article-title":"Evaluation of long-lasting potential of Suprachoroidal Axitinib suspension via ocular and systemic disposition in rabbits","author":"Kansara","year":"2021","journal-title":"Transl. Vis. Sci. Technol."},{"issue":"7","key":"10.1016\/j.jconrel.2022.05.061_bb0275","first-page":"4925","article-title":"Pharmacokinetics and ocular tolerability of Suprachoroidal CLS-AX (axitinib injectable suspension) in rabbits","volume":"61","author":"Muya","year":"2020","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2022.05.061_bb0280","article-title":"Suprachoroidal injection of triamcinolone acetonide suspension: ocular pharmacokinetics and distribution in rabbits (accepted)","author":"Muya","year":"2022","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"15","key":"10.1016\/j.jconrel.2022.05.061_bb0285","first-page":"5063","article-title":"Suprachoroidal microinjection delivers triamcinolone acetonide to therapeutically-relevant posterior ocular structures and limits exposure in the anterior segment","volume":"54","author":"Edelhauser","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2022.05.061_bb0290","first-page":"5259","article-title":"Intraocular distribution and targeting of triamcinolone Acetonide suspension administered into the Suprachoroidal space","volume":"55","author":"Edelhauser","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2022.05.061_bb0295","article-title":"Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model","author":"Chen","year":"2015","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.jconrel.2022.05.061_bb0300","first-page":"3694","article-title":"Ocular pharmacokinetics and safety of Suprachoroidal A01017, small molecule complement inhibitor, injectable suspension in rabbits","volume":"61","author":"Hancock","year":"2020","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2022.05.061_bb0305","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/13543784.2020.1723078","article-title":"Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment","volume":"29","author":"Bhatwadekar","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jconrel.2022.05.061_bb0310","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.exer.2016.02.010","article-title":"Axitinib inhibits retinal and choroidal neovascularization in in vitro and in vivo models","volume":"145","author":"Giddabasappa","year":"2016","journal-title":"Exp. Eye Res."},{"issue":"8","key":"10.1016\/j.jconrel.2022.05.061_bb0315","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/17425247.2016.1182488","article-title":"Delivery of steroids into the eye for the treatment of macular edema","volume":"13","author":"Hadayer","year":"2016","journal-title":"Expert Opin Drug Deliv."},{"issue":"8","key":"10.1016\/j.jconrel.2022.05.061_bb0320","first-page":"133","article-title":"The role of the complement system in age-related macular degeneration","volume":"111","author":"Weber","year":"2014","journal-title":"Dtsch. Arztebl. Int."},{"issue":"7","key":"10.1016\/j.jconrel.2022.05.061_bb0325","first-page":"3977","article-title":"Suprachoroidal CLS-AX (axitinib injectable suspension), as a potential long-acting therapy for Neovascular age-related macular degeneration (nAMD)","volume":"61","author":"Kaiser","year":"2020","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"9","key":"10.1016\/j.jconrel.2022.05.061_bb0330","first-page":"2909","article-title":"Suprachoroidally delivered non-viral DNA nanoparticles transfect chorioretinal cells in non-human primates and rabbits","volume":"60","author":"Kansara","year":"2019","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"9","key":"10.1016\/j.jconrel.2022.05.061_bb0335","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3928\/23258160-20180831-07","article-title":"Suprachoroidal space alterations following delivery of triamcinolone acetonide: post-hoc analysis of the phase 1\/2 HULK study of patients with diabetic macular edema","volume":"49","author":"Lampen","year":"2018","journal-title":"Ophthalmic Surg. Lasers Imaging Retin."},{"key":"10.1016\/j.jconrel.2022.05.061_bb0340","series-title":"Safety of Suprachoroidal Injection Procedure Via Microinjector across Three Retinal Disorders Method for Post Hoc Analysis \u2022 Suprachoroidal Injection (SCI) Data Analyzed from 8 Clinical Trials Involving 3 Diseases","author":"Hu","year":"2021"},{"key":"10.1016\/j.jconrel.2022.05.061_bb0345","first-page":"1","article-title":"Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA)","author":"Khurana","year":"2021","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2022.05.061_bb0350","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jconrel.2016.02.041","article-title":"Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma","volume":"228","author":"Chiang","year":"2016","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.061_bb0355","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3390\/jfb6020379","article-title":"Lipid nanoparticles for ocular gene delivery","volume":"6","author":"Wang","year":"2015","journal-title":"J. Funct. Biomater."},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.061_bb0360","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1089\/jop.2012.0128","article-title":"Lipid nanoparticles as drug\/gene delivery systems to the retina","volume":"29","author":"del Pozo-Rodr\u00edguez","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther. Off. J. Assoc. Ocul. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.jconrel.2022.05.061_bb0365","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1167\/iovs.10-6291","article-title":"Pharmacokinetics of pars Plana intravitreal injections versus microcannula Suprachoroidal injections of bevacizumab in a porcine model","volume":"52","author":"Olsen","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"5","key":"10.1016\/j.jconrel.2022.05.061_bb0370","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1167\/iovs.17-23758","article-title":"Targeted drug delivery in the Suprachoroidal space by swollen hydrogel pushing","volume":"59","author":"Jung","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2022.05.061_bb0375","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2018.03.001","article-title":"Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle","volume":"277","author":"Jung","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.05.061_bb0380","article-title":"Use of rabbit eyes in pharmacokinetic studies of intraocular drugs","volume":"no. 113","author":"Ahn","year":"2016","journal-title":"J. Vis. Exp."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922004151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922004151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:38:12Z","timestamp":1759163892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922004151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":73,"alternative-id":["S0168365922004151"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.05.061","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.05.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}